Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients (ESCVHSCT)
Hematopoietic Stem Cell Transplantation (HSCT), COVID-19 Vaccines, Immune System Tolerance
About this trial
This is an interventional prevention trial for Hematopoietic Stem Cell Transplantation (HSCT) focused on measuring hematopoietic stem cell transplantation, SARS-CoV-2 specific IgG , immune reconstitution, COVID-19 vaccine efficacy
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years, successfully engraftment with full donor chimerism, absence of grade 3,4 acute GvHD or severe extensive chronic GvHD, no receive more than 0.5 mg/kg prednisolone, and no positive RT-PCR test for COVID-19 following HSCT
Exclusion Criteria:
Patients who are not candidates for the COVID-19 vaccine after transplantation due to severe complications.
Patients who do not consent to vaccination after transplantation
Sites / Locations
- Hematology, Oncology, and Stem Cell Transplantation Research Center of shariaty HospitalRecruiting
Arms of the Study
Arm 1
Experimental
vaccine
Patients who are a candidate for HSCT within the the Hematology, Oncology, and Stem Cell Transplantation Research Center of Shariaty Hospital, and agree to be vaccinated with an approved vaccine against the COVID-19 virus.